

REMARKS

Reconsideration of this application, as amended, is respectfully requested.

Claims 53- 58 and 60-83 are pending in the present application.

Claims 53-58, 60-73 and 76-83 have been allowed.

Claims 74 and 75 have been rejected.

In the present amendment, claims 74 and 75 have been amended. Support for this amendment is in the specification as filed and as detailed below. Therefore, entry of this amendment is respectfully requested.

The Examiner noted that the drawings, filed on March 15, 2004, have been accepted. Also, the Examiner noted that the terminal disclaimers filed February 3, 2006 have been approved.

Finally, and only for Applicants' internal docketing purposes, Applicants' representative has changed the docket number for this application from PC20701C to PC20702C.

SEQUENCE LISTING

According to the Examiner, the present application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR §1.821(a)(1) and (a)(2); however, this application fails to comply with the requirements of 37 CFR §1.821 through 1.825 for the following reasons: The sequence listing filed February 3, 2006 was not approved for the reasons set forth in the attached Raw Sequence Listing Error Report.

The Examiner stated that Applicant must provide a substitute computer readable form (CRF) copy of the Sequence Listing, a substitute paper copy of the Sequence Listing as well as an amendment directing its entry into the specification, and a statement that the content of the paper and computer readable copies are the same and include no new matter as required by 37 CFR §1.825(a) and (b).

With the present Amendment, Applicants have corrected the errors in the paper copy of the Sequence Listing and have included herewith a substitute paper copy of the Sequence Listing. Applicants have also included, by Express Mail, a substitute computer readable form (CRF) copy of the Sequence Listing.

Applicants' representative would request that the paper copy and the computer readable form copy of the sequence listing presently on file be replaced with the paper copy and the computer readable form copy of the substitute sequence listing submitted herewith. It is hereby

stated that the substitute sequence listing does not go beyond the disclosure of the present application and, therefore, does not constitute new matter. Accordingly, entry thereof in the present application is respectfully requested.

As Applicants' representative, I hereby state that the content of the paper copy and the computer readable form copy of the substitute sequence listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e) and 37 CFR §1.825(a) and (b), are the same.

AMENDMENT TO THE SPECIFICATION

With the above amendment to the specification, the substitute paper copy of the Sequence Listing has been entered into the present application.

No new matter has been introduced with the present amendment to the specification. Entry of this amendment to the specification is respectfully requested.

REJECTION UNDER 35 USC §112, SECOND PARAGRAPH

Claims 74 and 75 have been rejected under 35 USC 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The Examiner noted that claims 74 and 75 depend, in part, on canceled claim 59.

With the above amendments to the claims, Applicants have revised the dependency of claims 74 and 75, so these claims are no longer dependent on canceled claim 59. Applicants assert that no new matter has been introduced with this present amendment to the claims and their entry is respectfully requested.

The Examiner had noted that claims 74 and 75 would be allowable if rewritten or amended to overcome the rejection(s) under 35 USC §112, second paragraph, set forth in this office action. With the above amendment, Applicants believe they have overcome this rejection of the claims and respectfully request their allowance.

CONCLUSION

On the basis of the above amendments and remarks, reconsideration of this application, as amended, and its early allowance, are respectfully requested.

Respectfully submitted,

Date: 9/7/06

Martha A. Gammill

Martha A. Gammill
Attorney for Applicants
Reg. No. 31,820
Pfizer Inc.
Patent Department
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-5940
Fax (734) 622-1553